Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ra Capital Management, L.P. Sells 101,151 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ra Capital Management, L.P. sold 101,151 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $0.64, for a total transaction of $64,736.64. Following the sale, the insider directly owned 406,282 shares in the company, valued at $260,020.48. The trade was a 19.93% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. sold 87,490 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $58,618.30.
• On Friday, May 8th, Ra Capital Management, L.P. sold 376,526 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.71, for a total transaction of $267,333.46.

Werewolf Therapeutics Stock Down 4.3%

Shares of HOWL stock traded down $0.03 during trading hours on Tuesday, hitting $0.63. 500,207 shares of the company’s stock traded hands, compared to its average volume of 436,209. The stock’s fifty day simple moving average is $0.81 and its two-hundred day simple moving average is $0.84. Werewolf Therapeutics, Inc. has a 12-month low of $0.53 and a 12-month high of $2.38. The stock has a market cap of $30.71 million, a price-to-earnings ratio of -0.51 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, equities analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its stake in shares of Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares during the last quarter. Susquehanna International Group LLP grew its stake in shares of Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares during the period. Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the third quarter valued at approximately $304,000. Vanguard Group Inc. raised its holdings in shares of Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock valued at $2,774,000 after purchasing an additional 109,796 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the last quarter. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.